AI Science Tracker
EN

Predicting likelihood of in vivo chemotherapy response in canine lymphoma using ex vivo drug sensitivity and immunophenotyping data in a machine learning model

ImpriMed, Inc., Palo Alto, California, USA. · 20 Oct 2020 · medicine

Discovery

Predicting likelihood of in vivo chemotherapy response in canine lymphoma using ex vivo drug sensitivity and immunophenotyping data in a machine learning model

Source check: Source checked. Not independent scientific confirmation.

Finding: Random forest modeling of ex-vivo drug sensitivity and immunophenotyping predicted observed chemotherapy response in canine lymphoma patients, with a held-out evaluation.

Technology: Random-forest modeling predicts canine lymphoma chemotherapy response from ex-vivo drug sensitivity and immunophenotyping.

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
Random-forest modeling predicts canine lymphoma chemotherapy response from ex-vivo drug sensitivity and immunophenotyping.
Test and result
Methods describe 261 patients, ex-vivo assays, features and model evaluation; Results compare predictions with clinical response in the held-out set.
Limitation / still unknown
Methods describe 261 patients, ex-vivo assays, features and model evaluation; Results compare predictions with clinical response in the held-out set.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pmc&id=PMC7894155 · https://pubmed.ncbi.nlm.nih.gov/33025640/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.